as 07-04-2025 10:37am EST
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Founded: | 2016 | Country: | United States |
Employees: | N/A | City: | LOS ALTOS |
Market Cap: | 91.0M | IPO Year: | 2021 |
Target Price: | $63.75 | AVG Volume (30 days): | 1.5M |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.60 | EPS Growth: | N/A |
52 Week Low/High: | $2.02 - $11.00 | Next Earning Date: | 08-13-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1458.53% |
UNCY Breaking Stock News: Dive into UNCY Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
MT Newswires
18 days ago
GlobeNewswire
18 days ago
Simply Wall St.
24 days ago
MT Newswires
25 days ago
MT Newswires
25 days ago
MT Newswires
25 days ago
GlobeNewswire
25 days ago
The information presented on this page, "UNCY Unicycive Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.